|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aithal A, Rauth S, Kshirsagar P, Shah A,
Lakshmanan I, Junker WM, Jain M, Ponnusamy MP and Batra SK: MUC16
as a novel target for cancer therapy. Expert Opin Ther Targets.
22:675–686. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Baek MH, Lee SW, Park JY, Rhim CC, Kim DY,
Suh DS, Kim JH, Kim YM, Kim YT and Nam JH: Preoperative predictive
factors for complete cytoreduction and survival outcome in
epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant
chemotherapy. Int J Gynecol Cancer. 27:420–429. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Markman M, Federico M, Liu PY, Hannigan E
and Alberts D: Significance of early changes in the serum CA-125
antigen level on overall survival in advanced ovarian cancer.
Gynecol Oncol. 103:195–198. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Henderson JT, Webber EM and Sawaya GF:
Screening for ovarian cancer: Updated evidence report and
systematic review for the US preventive services task force. JAMA.
319:595–606. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Thériault C, Pinard M, Comamala M,
Migneault M, Beaudin J, Matte I, Boivin M, Piché A and Rancourt C:
MUC16 (CA125) regulates epithelial ovarian cancer cell growth,
tumorigenesis and metastasis. Gynecol Oncol. 121:434–443.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Coelho R, Marcos-Silva L, Ricardo S, Ponte
F, Costa A, Lopes JM and David L: Peritoneal dissemination of
ovarian cancer: Role of MUC16-mesothelin interaction and
implications for treatment. Expert Rev Anticancer Ther. 18:177–186.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Comamala M, Pinard M, Thériault C, Matte
I, Albert A, Boivin M, Beaudin J, Piché A and Rancourt C:
Downregulation of cell surface CA125/MUC16 induces
epithelial-to-mesenchymal transition and restores EGFR signalling
in NIH: OVCAR3 ovarian carcinoma cells. Br J Cancer. 104:989–999.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gubbels JA, Belisle J, Onda M, Rancourt C,
Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, et
al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent
interaction that facilitates peritoneal metastasis of ovarian
tumors. Mol Cancer. 5(50)2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shah JS, Gard GB, Yang J, Maidens J,
Valmadre S, Soon PS and Marsh DJ: Combining serum microRNA and
CA-125 as prognostic indicators of preoperative surgical outcome in
women with high-grade serous ovarian cancer. Gynecol Oncol.
148:181–188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jacobs IJ, Fay TN, Stabile I, Bridges JE,
Oram DH and Grudzinskas JG: The distribution of CA 125 in the
reproductive tract of pregnant and non-pregnant women. Br J Obstet
Gynaecol. 95:1190–1194. 1988.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Buamah P: Benign conditions associated
with raised serum CA-125 concentration. J Surg Oncol. 75:264–265.
2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bast RC Jr, Klug TL, St John E, Jenison E,
Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker
L, et al: A radioimmunoassay using a monoclonal antibody to monitor
the course of epithelial ovarian cancer. N Engl J Med. 309:883–887.
1983.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Matte I, Garde-Granger P, Bessette P and
Piché A: Ascites from ovarian cancer patients stimulates MUC16
mucin expression and secretion in human peritoneal mesothelial
cells through an Akt-dependent pathway. BMC Cancer.
19(406)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Worzfeld T, Pogge von Strandmann E, Huber
M, Adhikary T, Wagner U, Reinartz S and Müller R: The unique
molecular and cellular microenvironment of ovarian cancer. Front
Oncol. 7(24)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Savant SS, Sriramkumar S and O'Hagan HM:
The role of inflammation and inflammatory mediators in the
development, progression, metastasis, and chemoresistance of
epithelial ovarian cancer. Cancers (Basel). 10(251)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sanguinete MMM, Oliveira PH, Martins-Filho
A, Micheli DC, Tavares-Murta BM, Murta EFC and Nomelini RS: Serum
IL-6 and IL-8 correlate with prognostic factors in ovarian cancer.
Immunol Invest. 46:677–688. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kampan NC, Madondo MT, McNally OM,
Stephens AN, Quinn MA and Plebanski M: Interleukin 6 present in
inflammatory ascites from advanced epithelial ovarian cancer
patients promotes tumor necrosis factor receptor 2-expressing
regulatory T cells. Front Immunol. 8(1482)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Isobe A, Sawada K, Kinose Y, Ohyagi-Hara
C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, et
al: Interleukin 6 receptor is an independent prognostic factor and
a potential therapeutic target of ovarian cancer. PLoS One.
10(e0118080)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhu X, Shen H, Yin X, Long L, Chen X, Feng
F, Liu Y, Zhao P, Xu Y, Li M, et al: IL-6R/STAT3/miR-204 feedback
loop contributes to cisplatin resistance of epithelial ovarian
cancer cells. Oncotarget. 8:39154–39166. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
So KA, Min KJ, Hong JH and Lee JK:
Interleukin-6 expression by interactions between gynecologic cancer
cells and human mesenchymal stem cells promotes
epithelial-mesenchymal transition. Int J Oncol. 47:1451–1459.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in
human cervical and ovarian cancer cell lines by cytokines, inducers
and inhibitors. Oncol Rep. 23:605–614. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yang WL, Godwin AK and Xu XX: Tumor
necrosis factor-alpha-induced matrix proteolytic enzyme production
and basement membrane remodeling by human ovarian surface
epithelial cells: Molecular basis linking ovulation and cancer
risk. Cancer Res. 64:1534–1540. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Morgado M, Sutton MN, Simmons M, Warren
CR, Lu Z, Constantinou PE, Liu J, Francis LL, Conlan RS, Bast RC Jr
and Carson DD: Tumor necrosis factor-α and interferon-γ stimulate
MUC16 (CA125) expression in breast, endometrial and ovarian cancers
through NFκB. Oncotarget. 7:14871–14884. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Albertsmeyer AC, Kakkassery V,
Spurr-Michaud S, Beeks O and Gipson IK: Effect of pro-inflammatory
mediators on membrane-associated mucins expressed by human ocular
surface epithelial cells. Exp Eye Res. 90:444–451. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lang K, Niggemann B, Zanker KS and
Entschladen F: Signal processing in migrating T24 human bladder
carcinoma cells: Role of the autocrine interleukin-8 loop. Int J
Cancer. 99:673–680. 2002.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444.
2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kisielewski R, Tołwińska A, Mazurek A and
Laudański P: Inflammation and ovarian cancer-current views. Ginekol
Pol. 84:293–297. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Browning L, Patel MR, Horvath EB, Tawara K
and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in
promotion of metastasis. Cancer Manag Res. 10:6685–6693.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W
and Yao Z: Regulatory effect of e2, IL-6 and IL-8 on the growth of
epithelial ovarian cancer cells. Cell Mol Immunol. 2:365–372.
2005.PubMed/NCBI
|
|
36
|
Kulbe H, Hagemann T, Szlosarek PW,
Balkwill FR and Wilson JL: The inflammatory cytokine tumor necrosis
factor-alpha regulates chemokine receptor expression on ovarian
cancer cells. Cancer Res. 65:10355–10362. 2005.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang F, Wang H, Jin D and Zhang Y: Serum
miR-17, IL-4, and IL-6 levels for diagnosis of endometriosis.
Medicine (Baltimore). 97(e10853)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jiang J, Jiang Z and Xue M: Serum and
peritoneal fluid levels of interleukin-6 and 37 as biomarkers for
endometriosis. Gynecol Endocrinol. 35:571–575. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tortorella C, Piazzolla G, Matteo M, Pinto
V, Tinelli R, Sabbà C, Fanelli M and Cicinelli E: Interleukin-6,
1β, and tumor necrosis factor α in menstrual effluents as
biomarkers of chronic endometritis. Fertil Steril. 101:242–247.
2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139.
2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Seo KY, Chung SH, Lee JH, Park MY and Kim
EK: Regulation of membrane-associated mucins in the human corneal
epithelial cells by dexamethasone. Cornea. 26:709–714.
2007.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bauer J, Lengyel G, Bauer TM, Acs G and
Gerok W: Regulation of interleukin-6 receptor expression in human
monocytes and hepatocytes. FEBS Lett. 249:27–30. 1989.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Takizawa H, Ohtoshi T, Yamashita N, Oka T
and Ito K: Interleukin 6-receptor expression on human bronchial
epithelial cells: Regulation by IL-1 and 6. Am J Physiol.
270:L346–L352. 1996.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Böttger E, Grangeiro de Carvalho E, Meese
S, Kun JF and Esen M: Expression of interleukin-6 family receptors
in NK92 cells is regulated by cytokines and not through direct
interaction with Plasmodium falciparum-infected erythrocytes. J
Interferon Cytokine Res. 33:65–71. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Liu CC, Jewett MC, Chin JW and Voigt CA:
Toward an orthogonal central dogma. Nat Chem Biol. 14:103–106.
2018.PubMed/NCBI View Article : Google Scholar
|
